IL6 and type 2 diabetes mellitus: Herder and coworkers reported a significant increase of circulating MIF, CRP, and interleukin-6 (IL-6) in subjects with impaired glucose tolerance (IGT; n = 242) or T2D (n = 236) compared to normoglycemic controls (n = 244) (KORA S4 study; participants aged 55–74 years) [26].